Business Wire

LIB Therapeutics Appoints David Cory as Chief Executive Officer as Lead Clinical Programs Achieve Phase 3 Completion

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics Inc. (LIB), a late-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor therapies for patients at very high and high-risk of ...
pharmaphorum

LIB takes aim at cholesterol market with new PCSK9 option

Privately-held drug developer LIB Therapeutics has claimed FDA approval for a new once-monthly PCSK9 inhibitor – Lerochol – that can be used to reduce cholesterol levels. The injectable product has ...
Business Wire

LIB Therapeutics Announces Publication of Phase 3 Study of Lerodalcibep in Homozygous Familial Hypercholesterolemia (HoFH) in Lancet Diabetes & Endocrinology

LIBerate-HoFH study was part of a global registration-enabling Phase 3 program of > 2,900 patients Biologics license application for lerodalcibep submitted to FDA in December 2024 ...
FiercePharma

Cincinnati's LIB scores FDA approval for 3rd-generation PCSK9 drug Lerochol

LIB Therapeutics has scored an FDA approval for its cholesterol-lowering, third-generation PCSK9 inhibitor, lerodalcibep-liga. The injected treatment, which will carry the commercial name Lerochol, is ...